58 results on '"Federica Botta"'
Search Results
2. Oxidative stress and antioxidant defence in a healthy nonagenarian population
- Author
-
Federica Botta, Damiano Cottalasso, Stefania Patriarca, Nicola Traverso, Paolo Carlier, Umberto M. Marinari, Luigi Fontana, Anna Lisa Furfaro, Maria Adelaide Pronzato, and Emanuela Balbis
- Subjects
Adult ,Aging ,Antioxidant ,Physiology ,medicine.medical_treatment ,Clinical Biochemistry ,Population ,Oxidative phosphorylation ,medicine.disease_cause ,Biochemistry ,Antioxidants ,chemistry.chemical_compound ,Reference Values ,medicine ,Humans ,Sulfhydryl Compounds ,education ,Aged ,Glutathione Transferase ,Aged, 80 and over ,chemistry.chemical_classification ,education.field_of_study ,Chemistry ,Healthy population ,Glutathione peroxidase ,Biochemistry (medical) ,Cell Biology ,Glutathione ,Middle Aged ,Oxidative Stress ,Italy ,Ageing ,Immunology ,Biomarkers ,Oxidative stress - Abstract
Results on oxidative markers during ageing are not consistent throughout the scientific literature; however, successful ageing may depend on better ability to cope with oxidative stress. A previous study of ours showed that successful ageing could actually be related to enhanced response to oxidatively modified proteins. In this study, a healthy nonagenarian population (OVER-90) was examined for various blood oxidative biomarkers and compared with a healthy population of blood donors (age range, 23-66 years). Blood glutathione, both total (tGSH) and oxidised (GSSG), and total plasmatic antioxidant status were maintained in the OVER-90 at a level similar to the control population. Sulphydryl (sulfhydryl) groups and glutathione peroxidase (GPx) were instead decreased. The results are discussed in a possible unifying view: the OVER-90 population could possess a globally preserved antioxidant ability, though some signs of oxidative damage are present and some structures could be 'sacrificed' in order to keep the redox equilibrium.
- Published
- 2007
3. Influence of 1-Week Helicobacter pylori Eradication Therapy with Rabeprazole, Clarithromycin, and Metronidazole on 13C-Aminopyrine Breath Test
- Author
-
Federica Malfatti, Edoardo G. Giannini, Emanuela Testa, Federica Botta, Mario Mamone, Simone Polegato, Roberto Testa, Alessandra Fumagalli, and Vincenzo Savarino
- Subjects
Male ,medicine.medical_specialty ,Physiology ,Population ,Rabeprazole ,Pharmacology ,Gastroenterology ,2-Pyridinylmethylsulfinylbenzimidazoles ,Helicobacter Infections ,Anti-Infective Agents ,Cytochrome P-450 Enzyme System ,Liver Function Tests ,Clarithromycin ,Metronidazole ,Internal medicine ,medicine ,Humans ,Drug Interactions ,Enzyme Inhibitors ,Aminopyrine ,education ,Aged ,Antibacterial agent ,Breath test ,Carbon Isotopes ,education.field_of_study ,Helicobacter pylori ,medicine.diagnostic_test ,biology ,Chemistry ,Middle Aged ,biology.organism_classification ,Anti-Bacterial Agents ,Breath Tests ,Liver ,Benzimidazoles ,Drug Therapy, Combination ,Female ,Liver function ,Omeprazole ,medicine.drug - Abstract
Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C-aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (to), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 +/- 5.4, t8 = 13.5 +/- 4.0, t38 = 16.1 +/- 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 +/- 1.1, t8 = 2.4 +/- 0.8, t38 = 2.6 +/- 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.
- Published
- 2005
4. C-galactose breath test and C-aminopyrine breath test for the study of liver function in chronic liver disease
- Author
-
Roberto Testa, Alessandra Fumagalli, Federica Botta, Domenico Risso, Edoardo G. Giannini, Tiziana Cotellessa, Federica Malfatti, Emanuela Testa, Simone Polegato, Paolo Borro, Alberto Fasoli, and Sara Milazzo
- Subjects
Breath test ,medicine.medical_specialty ,Cirrhosis ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Gold standard (test) ,medicine.disease ,Chronic liver disease ,Surgery ,Liver biopsy ,Internal medicine ,medicine ,Etiology ,In patient ,Liver function ,business - Abstract
Background & Aims: Liver biopsy examination is the gold standard to diagnose the presence of cirrhosis. The aim of this study was to evaluate the accuracy of both 13C-aminopyrine breath test (13C-ABT) and 13C-galactose breath test (13C-GBT) in the noninvasive assessment of the presence of cirrhosis in patients with chronic liver disease. Methods: We evaluated 61 patients with chronic liver disease of diverse etiologies (21 compensated cirrhosis). All patients underwent 13C-GBT and 13C-ABT, and the results were expressed as a percentage of the administered dose of 13C recovered per hour (%dose/h) and as the cumulative percentage of administered dose of 13C recovered over time (%dose cumulative). Results were analyzed according to absence vs presence of cirrhosis. Results: On average, 13C-GBT %dose/h and %dose cumulative were decreased significantly in patients with compensated cirrhosis, and the same finding was observed for 13C-ABT results from 30 to 120 minutes. 13C-GBT %dose/h at 120 minutes had 71.4% sensitivity, 85.0% specificity, and 83.7% accuracy, whereas 13C-ABT %dose cumulative at 30 minutes had 85.7% sensitivity, 67.5% specificity, and 77.1% accuracy for distinguishing between the 2 subgroups of patients. Combined assessment of 13C-GBT and 13C-ABT increased the diagnostic accuracy (80% positive predictive value) of either test alone and reached 92.5% specificity and 100% sensitivity for the diagnosis of cirrhosis. Conclusions: In patients with chronic liver disease, both 13C-GBT and 13C-ABT are useful for the diagnosis of cirrhosis. Combination of the tests increases the diagnostic yield of each test alone.
- Published
- 2005
5. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatm
- Author
-
Edoardo G. Giannini, Domenico Risso, Simone Polegato, Bruno Chiarbonello, Alessandra Fumagalli, Elena Podestà, G. De Caro, Emanuela Testa, Paola Romagnoli, Roberto Testa, Federica Botta, Federica Malfatti, and G. Cittadini
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,Palliative care ,Gastroenterology ,Liver disease ,Model for End-Stage Liver Disease ,Internal medicine ,medicine ,Carcinoma ,Humans ,Pharmacology (medical) ,Chemoembolization, Therapeutic ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Hepatology ,business.industry ,Liver Neoplasms ,Palliative Care ,Cancer ,Middle Aged ,medicine.disease ,Survival Analysis ,body regions ,Treatment Outcome ,Hepatocellular carcinoma ,Female ,business ,Liver Failure - Abstract
Summary Background: Trans-catheter arterial chemoembolisation (TACE) is the most common palliative treatment for hepatocellular carcinoma (HCC). The therapeutic options depend both on the characteristics of the tumour and on functional staging of the cirrhosis. Aim: To evaluate the effects of TACE on the survival of cirrhotic patients with HCC according to different staging systems [Okuda score, Cancer Liver Italian Program (CLIP) score, Model for End-stage Liver Disease (MELD) score] and in relation to the side-effects of TACE. Methods: Fifty cirrhotic patients, 36 CTP class A and 14 class B, underwent 106 TACE treatments with mitoxantrone. Survival at 12, 24, and 36 months was evaluated. Results: MELD at 12 months and CLIP at 24 months were identified as significant variables associated with survival. Combined cut-offs of CLIP and of MELD identified four subgroups of patients with different survivals, at 12, 24 and 36 months, respectively: CLIP ≥ 2 and MELD ≥ 10 (63%, 20% and 0%), CLIP
- Published
- 2003
6. [Untitled]
- Author
-
Bruno Chiarbonello, Paola Romagnoli, Roberto Testa, Federica Botta, Vincenzo Savarino, Federica Malfatti, Edoardo G. Giannini, Alberto Fasoli, and Mario Mamone
- Subjects
medicine.medical_specialty ,Gastric Infection ,Cirrhosis ,biology ,medicine.diagnostic_test ,Physiology ,Gastroenterology ,Hepatitis C ,Hepatology ,Helicobacter pylori ,medicine.disease ,biology.organism_classification ,digestive system diseases ,Liver disease ,Internal medicine ,Immunology ,medicine ,Helicobacter ,Liver function tests - Abstract
Helicobacter pylori gastric infection has been associated with various digestive and extradigestive diseases. In liver disease bacterial infections have been associated with impairment of cytochrome P-450 liver metabolic activity. Moreover, infection by Helicobacter spp. seems to be linked with the development of hepatocellular carcinoma (HCC) in mice. Our aims were to evaluate the influence of H. pylori infection on cytochrome P-450 liver metabolic activity as assessed by means of monoethylglycinexylidide (MEGX) test and to assess the prevalence of H. pylori infection in patients with HCC. Ninety-six hepatitis C virus (HCV) -positive cirrhotic patients, 36 of whom had HCC, were tested for H. pylori infection by means of anti-H. pylori IgG. Patients underwent the MEGX test. Characteristics of the patients were then analyzed on the basis of the presence of H. pylori infection. Seroprevalence of H. pylori infection was similar between cirrhotic patients without (68%) or with (63.8%) HCC. Mean MEGX values were significantly (P < 0.0001) lower in H. pylori infected patients (18.2 +/- 13.9 ng/ml) as compared to the noninfected ones (46.9 +/- 17.1 ng/ml), independently of Child-Pugh's classification. These differences persisted even after subdividing patients according to the presence of HCC. In conclusion, in anti-HCV positive cirrhotic patients H. pylori infection is associated to an impairment of cytochrome P-450 liver metabolic activity. Seroprevalence of H. pylori infection in HCC patients is similar to that observed in tumor-free cirrhotics.
- Published
- 2003
7. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis
- Author
-
Paola Romagnoli, Emanuela Testa, Edoardo G. Giannini, Paolo Borro, Mario Mamone, Roberto Testa, Simone Polegato, Federica Botta, Alessandra Fumagalli, Federica Malfatti, Bruno Chiarbonello, and Elena Podestà
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Hepatitis C virus ,medicine.disease_cause ,Gastroenterology ,Pathogenesis ,Necrosis ,Fibrosis ,Internal medicine ,Humans ,Medicine ,Aminopyrine ,Thrombopoietin ,Breath test ,Carbon Isotopes ,Hepatology ,medicine.diagnostic_test ,Platelet Count ,business.industry ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Thrombocytopenia ,Breath Tests ,Liver ,Liver biopsy ,Immunology ,Female ,Liver function ,business ,Spleen - Abstract
Thrombocytopenia can be found in patients with chronic hepatitis related to hepatitis C virus (HCV). Both hypersplenism and decreased liver production of thrombopoietin (TPO) have been hypothesized as mechanisms responsible for thrombocytopenia.To assess the presence of relationships among platelet count, spleen size, TPO serum levels, liver histology, and liver function in a group of patients with HCV-related chronic hepatitis.Platelet count, TPO serum levels, and spleen size were assessed in 25 untreated HCV positive chronic hepatitis patients undergoing liver biopsy. These parameters were correlated to liver histology and liver function as evaluated by means of [(13)C]aminopyrine breath test (ABT).Both platelet counts (146 +/- 48 vs. 202 +/- 56 x 10(9)/1, P0.03) and TPO serum levels (103 +/- 24 vs. 158 +/- 7 1 pg/ml, P0.02) were lower among patients with high fibrosis scores as compared to patients with low fibrosis scores. Patients with thrombocytopenia as well as patients with high fibrosis scores had lower ABT results as compared to patients with normal platelet counts and patients with no or mild fibrosis, respectively. TPO serum levels were correlated to platelet count (r(s) = 0.493, P = 0.016), and negatively correlated to fibrosis stage (r(s) = -0.545, P = 0.008). Lastly, low TPO serum levels were associated to a decrease in liver function.Our study showed that in patients with chronic hepatitis related to HCV infection serum TPO levels are correlated to liver functional impairment and to the degree of liver fibrosis.
- Published
- 2002
8. 13 C-Aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection
- Author
-
Edoardo G. Giannini, Roberto Testa, Simone Polegato, Alberto Fasoli, Bruno Chiarbonello, Emanuela Testa, Federica Botta, Federica Malfatti, Paola Romagnoli, and Alessandra Fumagalli
- Subjects
Breath test ,medicine.medical_specialty ,Cirrhosis ,Hepatology ,medicine.diagnostic_test ,biology ,business.industry ,Hepatitis C virus ,Hepacivirus ,Gastroenterology ,Hepatitis C ,Chronic liver disease ,medicine.disease ,medicine.disease_cause ,biology.organism_classification ,Surgery ,Internal medicine ,medicine ,Pharmacology (medical) ,Liver function ,business - Abstract
Background: There are few data on the use of the 13C-aminopyrine breath test to evaluate the severity of disease in patients with hepatitis C virus-related chronic liver disease, although these patients represent one of the most important problems in clinical hepatology. Aims: To compare 13C-aminopyrine breath test results of patients with hepatitis C virus-related chronic hepatitis and Child–Pugh class A cirrhosis with those of normal subjects, and to evaluate different methods of expressing 13C-aminopyrine breath test results. Methods: Twenty-four patients with hepatitis C virus-related chronic hepatitis and 17 patients with Child–Pugh class A cirrhosis underwent 13C-aminopyrine breath test. Breath samples were collected every 30 min up to 2 h after 13C-aminopyrine administration. 13C-Aminopyrine breath test results were expressed as a percentage of the administered dose of 13C recovered per hour (% dose/h) and the cumulative percentage of administered dose of 13C recovered over time (% dose cum). Nineteen healthy subjects served as controls. Patients with hepatitis C virus-related chronic hepatitis were divided into subgroups on the basis of histological staging and grading. Results: The 13C-aminopyrine breath test result (% dose/h) at 30 min was significantly different among the three subgroups of subjects (normal subjects, 11.5 ± 3.5; chronic hepatitis patients, 8.1 ± 4.1; cirrhosis patients, 5.0 ± 3.1; P 2) fibrosis scores to be distinguished. The 13C-aminopyrine breath test results (% dose cum) at 30, 60 and 90 min allowed discrimination between normal subjects and chronic hepatitis and cirrhosis patients. The 13C-aminopyrine breath test result (% dose cum) was also able to distinguish between normal subjects and chronic hepatitis patients with high but not low fibrosis scores. Both 13C-aminopyrine breath test results (% dose/h and % dose cum) at 120 min allowed the differentiation between normal subjects and chronic hepatitis patients with high (≥ 6) necro-inflammatory activity. Conclusions: In patients with hepatitis C virus-related chronic liver disease, the 13C-aminopyrine breath test proved to be safe and easy to perform, and was able to evaluate different degrees of liver function impairment which were partly correlated to clinical and histological evaluation. In future studies, 13C-aminopyrine breath test results should be expressed in a standardized fashion to permit comparison.
- Published
- 2002
9. Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection
- Author
-
Vincenzo Savarino, Paolo Borro, Federica Botta, Roberto Testa, Bruno Chiarbonello, Simone Polegato, Alessandra Fumagalli, Edoardo G. Giannini, Alberto Fasoli, Federica Malfatti, Emanuela Testa, and Paola Romagnoli
- Subjects
Breath test ,medicine.medical_specialty ,Gastric Infection ,Cirrhosis ,Necrosis ,Hepatology ,biology ,medicine.diagnostic_test ,business.industry ,Spirillaceae ,Gastroenterology ,Helicobacter pylori ,medicine.disease ,biology.organism_classification ,Liver disease ,Internal medicine ,medicine ,Pharmacology (medical) ,Liver function ,medicine.symptom ,business - Abstract
Background: Helicobacter pylori gastric infection has been associated with various digestive and extra-digestive diseases. The systemic influence of gastric H. pylori infection seems to be mediated by the release of various cytokines. In liver disease, bacterial infections have been associated with the impairment of liver metabolic function. Aims: To evaluate the influence of H. pylori infection on liver function as assessed by means of the monoethylglycinexylidide test, which depends upon liver blood flow and cytochrome P-450 activity, and the 13C-galactose breath test, which depends on cytosolic enzymatic activity and is correlated with hepatic functional mass. Moreover, to evaluate whether H. pylori-associated modifications of liver function may be related to tumour necrosis factor-α serum levels. Patients and methods: Thirty-five patients with liver cirrhosis of various aetiologies, who underwent monoethylglycinexylidide and 13C-galactose breath tests, were retrospectively evaluated for H. pylori infection by means of anti-H. pylori immunoglobulin G. The main clinical, biochemical and functional characteristics of the patients as well as their tumour necrosis factor-α serum levels were then analysed on the basis of the presence of H. pylori infection. Results: Twenty-one patients tested positive for H. pylori infection (60%), and 11 tested negative (31.4%). No clinical or biochemical differences were observed between H. pylori-infected and non-infected patients. H. pylori infection showed no difference in distribution according to Child–Pugh classes (A, 55%; B and C, 67%). The monoethylglycinexylidide test results were significantly lower at each sampling time in H. pylori-positive patients compared to H. pylori-negative patients (MEGX15, P=0.027; MEGX30, P=0.014; MEGX60, P=0.028), while 13C-galactose breath test showed no significant differences considering both cumulative percentage dose and percentage dose/h. The median tumour necrosis factor-α serum levels were no different between H. pylori-positive (16.1 pg/mL, 95% confidence interval, 8.7–28.7) and H. pylori-negative (12.3 pg/mL, 95% confidence interval, 8.7–23.4) patients. Conclusions: In cirrhotic patients, H. pylori infection seems to selectively affect cytochrome P-450 liver activity, while hepatic functional mass does not seem to be impaired. Tumour necrosis factor-α does not seem to be the mediator of this impairment. Further studies are needed to evaluate the impact of H. pylori eradication on parameters of liver function.
- Published
- 2001
10. Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: A functional study
- Author
-
Edoardo G. Giannini, Emanuela Testa, Roberto Testa, Paola Ceppa, Alberto Fasoli, Paola Romagnoli, and Federica Botta
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Hepatitis C virus ,Alpha interferon ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,Liver Function Tests ,Recurrence ,Interferon ,Internal medicine ,medicine ,Humans ,Platelet ,Hepatology ,medicine.diagnostic_test ,business.industry ,Interferon-alpha ,Lidocaine ,Immunotherapy ,Hepatitis C, Chronic ,Middle Aged ,Cytokine ,Liver ,Liver biopsy ,Immunology ,Female ,Liver function ,business ,Follow-Up Studies ,medicine.drug - Abstract
AIM To evaluate the long-term functional outcome of chronic hepatitis C (CHC) patients treated with interferon (IFN) therapy. METHODS Thirty-six patients with CHC were followed up for a mean of 36 months (+/- 19, SD) after a course of IFN therapy. Biochemical, virological (qualitative hepatitis C virus (HCV)-RNA and HCV genotype), and functional (monoethylglycinexylidide (MEGX) test) evaluations were carried out at the time of liver biopsy. Patients were divided into long-term responders (LTR), relapsers (RR), or non-responders (NR) according to IFN therapy outcome. At the end of follow up, patients were non-invasively re-evaluated by means of biochemistry, qualitative HCV-RNA, MEGX test, and liver ultrasonography. RESULTS A significant decrease in MEGX values was observed in all patients. However, when patients were examined according to treatment outcome, only NR and RR showed a significant decrease in liver function as compared to pretreatment levels (MEGX30, 80.5 +/- 26.8-62.9 +/- 24.2 ng/mL, P< 0.01; MEGX60, 72.9 +/- 18.1-60.5 +/- 19.7 ng/mL, P< 0.05; MEGXAUC, 3,816 +/- 1,243-3,095 +/- 1,205 ng/mL per h, P< 0.05). On the contrary, LTR patients showed no significant modifications in MEGX values at each sampling time (MEGX,5, 72.9 +/- 31.4-70.3 +/- 29.7 ng/mL; MEGX30, 84.0 +/- 27.6-71.5 +/- 21.8 ng/ mL; MEGX60, 69.5 +/- 26.8-63.2 +/- 14.4 ng/mL; MEGXAUC 4028 +/- 1,378-3,620 +/- 1,041 ng/mL per h). At the end of follow up, LTR patients showed normal liver biochemistry and negativity of serum HCV-RNA, while NR and RR patients showed a significant decrease in platelets. CONCLUSIONS In CHC patients long-term response to IFN therapy, besides favoring positive clinical and virologic long-term outcome, results in maintaining preserved liver function. Furthermore, IFN therapy seems to determine a decrease in the rate of functional disease progression, even in NR and RR. The MEGX test may be considered as a useful tool for performing serial follow up of CHC patients.
- Published
- 2001
11. [Untitled]
- Author
-
Paola Romagnoli, Andrea Pasini, Edoardo G. Giannini, Luca Mastracci, Alberto Fasoli, Ilaria Comino, Roberto Testa, Domenico Risso, Federica Botta, and Paola Ceppa
- Subjects
medicine.medical_specialty ,Pathology ,Bile acid ,Physiology ,medicine.drug_class ,Bile duct ,Gastroenterology ,Intrahepatic bile ducts ,Glutathione ,Biology ,Hepatology ,Lesion ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Internal medicine ,Genotype ,medicine ,Viral disease ,medicine.symptom - Abstract
Damage to bile ducts in chronic hepatitis C is a characteristic histological lesion. Moreover, the presence of abnormal levels of γGT in these patients is also a common finding. Assessing whether the presence of bile duct lesions is indicated by biochemical abnormalities or whether virological characteristics can influence their development may help in the definition of clinical–histological relationships in chronic hepatitis C. In this study we evaluated the relationships among routine biochemical parameters, serum bile acids, and pi-class glutathione S-transferase levels, and the presence of bile duct lesions in 60 patients with chronic hepatitis C. Furthermore, we assessed whether the presence of bile duct lesion might be related to HCV genotype, HCV-RNA serum levels, and positivity for HGV-RNA. We found that γGT was the only parameter related to the presence of bile duct lesions. Although a trend towards higher serum bile acids and pi-class glutathione S-transferase levels was observed in patients with bile duct lesions, this trend did not reach statistical significance. Different HCV genotypes and RNA levels, and HGV-RNA positivity did not seem to influence the presence of bile duct damage. In conclusion we found that γGT levels point out the presence of bile duct lesions in patients with chronic hepatitis C. Since we observed a different pattern of alteration of γGT, serum bile acids, and pi-class glutathione S-transferase, we suggest that these various biochemical alterations reflect a more complex damage to bile duct structures, which is not likely represented by the common assessment of bile duct lesions. Viral factors such as HCV genotype and RNA levels as well as HGV-RNA positivity are probably not the main cause of this histological damage.
- Published
- 2001
12. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C
- Author
-
P. B. Lantieri, Tommaso Barreca, Edoardo G. Giannini, Domenico Risso, Paola Ceppa, Federica Botta, Andrea Pasini, Giancarlo Icardi, Ilaria Comino, Roberto Testa, Luca Mastracci, and Paola Romagnoli
- Subjects
Adult ,Leptin ,Liver Cirrhosis ,Male ,Hepatitis, Viral, Human ,Hepacivirus ,macromolecular substances ,Severity of Illness Index ,Fibrosis ,Diabetes mellitus ,medicine ,Humans ,Hepatology ,business.industry ,musculoskeletal, neural, and ocular physiology ,Flaviviridae ,digestive, oral, and skin physiology ,Fatty liver ,Gastroenterology ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,Viral Load ,medicine.disease ,Obesity ,Fatty Liver ,Liver ,nervous system ,Case-Control Studies ,Immunology ,RNA, Viral ,Female ,Steatosis ,business ,Complication ,hormones, hormone substitutes, and hormone antagonists - Abstract
The presence of steatosis is a common histological finding in patients with chronic hepatitis C (CHC). The causes of the severity of this condition are not yet clear, although both metabolic and viral factors supposedly are involved. In this study our aim was to examine the possible influence that leptin levels, hepatitis C virus (HCV) RNA levels, and hepatitis G virus (HGV) infection have on the severity of steatosis and on the presence and degree of fibrosis in patients with CHC.One hundred eighty-two CHC patients with histological findings of steatosis were chosen from among a cohort of patients referred to our center for staging of liver disease. Among them 48 CHC patients were accurately selected so as to rule out possible confounding factors for the presence of steatosis (diabetes mellitus, hyperlipemia, obesity, alcohol). Leptin levels, HCV RNA levels, and HCV genotype, and the presence of HGV RNA were assessed in these patients and related to histological findings.We found that leptin levels in CHC patients were similar to those in healthy subjects. No relationship was found between leptin levels and severity of steatosis. HCV RNA levels, HCV genotype, and the presence of HGV infection were no different among CHC patients with various degrees of steatosis. Leptin was not related to different degrees of fibrosis, whereas higher viral load was the only parameter associated to higher fibrosis scores.These findings suggest that the degree of steatosis in patients with CHC does not seem to depend on serum leptin levels or on viral factors, at least as far as HCV viremia and genotype and HGV infection are concerned. The severity of fibrosis does not seem to be influenced by leptin levels, whereas HCV viral load does seem to play some role.
- Published
- 2000
13. Utility of α-Glutathione S-transferase assessment in chronic hepatitis C patients with near normal alanine aminotransferase levels
- Author
-
Alberto Fasoli, Federica Malfatti, Roberto Testa, Bruno Chiarbonello, Paola Ceppa, Domenico Risso, Edoardo G. Giannini, P. B. Lantieri, Federica Botta, and Paola Romagnoli
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Clinical Biochemistry ,α glutathione s transferase ,Biology ,Severity of Illness Index ,Gastroenterology ,Cohort Studies ,Chronic hepatitis ,Fibrosis ,Internal medicine ,medicine ,Humans ,In patient ,Alanine aminotransferase ,Aged ,Glutathione Transferase ,Alanine Transaminase ,Histology ,General Medicine ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Isoenzymes ,Liver ,Female ,Viral load ,Biomarkers - Abstract
Objectives: To study whether determining alpha-glutathione S-transferase (α-GST) might improve the assessment of chronic hepatitis C (CHC) patients with near normal alanine aminotransferase levels (NNA). Design and methods: We studied 119 viraemic CHC patients. They were subdivided into two groups according to the pattern of alanine aminotransferase (ALT) alteration, i.e. consistently above (HA) or below (NNA) twice the upper normal value. In these patients we assessed α-GST and correlated its levels to clinical, histological, and virological findings, further evaluating whether α-GST might improve the assessment of CHC patients with NNA. Results: α-GST showed a significant correlation with aminotransferases, though not with histological necroinflammatory activity and fibrosis or with hepatitis C virus RNA levels. Twenty-seven patients had NNA (23%), and within this subgroup of patients α-GST identified a subset of patients with a higher viral load. Conclusions: α-GST in CHC patients is related to hepatocellular necrosis parameters, but unrelated both to histology and to viraemia. However, in patients with NNA, α-GST identified a subgroup of patients with a higher viral load. In this subgroup of patients α-GST alteration likely represents the expression of a more severe damage. Because this injury is not detectable by the usual biochemical or histological work-up, we suggest that α-GST could a useful tool for monitoring liver damage over time.
- Published
- 2000
14. Chronic liver disease related to hepatitis C virus
- Author
-
Edoardo G. Giannini, Alberto Fasoli, Valentina Venturino, Elena Cresta, S. Caglieris, Paola Ceppa, Giancarlo Icardi, Federica Botta, P. B. Lantieri, Guido Celle, Domenico Risso, and Roberto Testa
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,Adolescent ,Genotype ,Hepatitis C virus ,Hepacivirus ,medicine.disease_cause ,Chronic liver disease ,Severity of Illness Index ,Gastroenterology ,Liver disease ,Internal medicine ,medicine ,Humans ,Aged ,Hepatitis ,Hepatology ,business.industry ,Liver Neoplasms ,Age Factors ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Hepatocellular carcinoma ,Immunology ,Disease Progression ,Female ,Viral disease ,business ,Viral load - Abstract
Background Hepatitis C virus infection accounts for varying severity of chronic liver disease. Clinical manifestations of infection have been related to different virus genotypes, with conflicting results. Design We performed a cross-sectional study on a Northern-Italian group of patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma related to hepatitis C virus infection in order to verify the association of different viral strains and the outcomes of viral disease. Methods Two hundred and seventy-one patients referred to our unit for liver disease were studied and clinical, biochemical, histological, and functional parameters were investigated. Results Different viral genotypes were not associated with peculiar findings in any of the degrees of liver disease. However, a progressive age increase was associated with disease severity, although clinical and functional staging of cirrhotic patients with hepatocellular carcinoma was better compared to tumour-free cirrhotic patients. There was an increased prevalence of genotype 1 b related to the age of the patients. In multivariate regression analysis the patients'age and apparent duration of infection were independently associated with the presence of cirrhosis and only the age of patients was associated to hepatocellular carcinoma. Conclusions In the population we studied age of the patients seemed to be a determinant conditioning disease severity, likely reflecting older infections and long-standing liver disease. The prevalence of certain genotypes in varying degrees of liver disease could be an epiphenomenon which might also be explained by the changing prevalence of infecting strains over the past decades.
- Published
- 1999
15. [Untitled]
- Author
-
P. B. Lantieri, Edoardo G. Giannini, Federica Botta, Guido Celle, Domenico Risso, Paola Ceppa, Alberto Fasoli, and Roberto Testa
- Subjects
medicine.medical_specialty ,Pathology ,Cirrhosis ,biology ,Physiology ,AST/ALT ratio ,business.industry ,Gastroenterology ,Aspartate transaminase ,Hepatitis C ,Hepatology ,Hepatitis B ,medicine.disease ,digestive system ,digestive system diseases ,chemistry.chemical_compound ,chemistry ,Fibrosis ,Internal medicine ,medicine ,biology.protein ,business ,Indocyanine green - Abstract
The ratio of serum aspartate aminotransferase to alanine aminotransferase (AST/ALT ratio) has been proposed as a noninvasive method of assessing liver fibrosis and cirrhosis. Our aims were to confirm the usefulness of the AST/ALT ratio in diagnosing cirrhosis noninvasively as well as to verify the existence of a relationship between the ratio and liver functional impairment. In all, 348 patients (177 with chronic hepatitis, 171 with cirrhosis) were retrospectively evaluated and the AST/ALT ratio was related to monoethyl glycine xylidide (MEGX) formation. Moreover, in a subgroup of 54 patients we analyzed the relationships among the AST/ALT ratio and indocyanine green clearance and half-life. The AST/ALT ratio was able to separate patients with mild fibrosis from those with severe fibrosis and cirrhosis. The AST/ALT ratio, MEGX, prothrombin activity, and platelet count were selected by multivariate analysis as variables associated with cirrhosis. The AST/ALT ratio showed significant correlations both with MEGX formation and with indocyanine green clearance and half-life. The alterations of indocyanine green kinetics, which depend upon liver blood flow and uptake, were likely due to progressive fibrosis. These findings might partially explain the increase in the AST/ALT ratio as disease progresses.
- Published
- 1999
16. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease
- Author
-
Edoardo G, Giannini, Alberto, Fasoli, Paolo, Borro, Federica, Botta, Federica, Malfatti, Alessandra, Fumagalli, Emanuela, Testa, Simone, Polegato, Tiziana, Cotellessa, Sara, Milazzo, Domenico, Risso, and Roberto, Testa
- Subjects
Adult ,Liver Cirrhosis ,Male ,Breath Tests ,Liver Function Tests ,Galactose ,Humans ,Female ,Middle Aged ,Aminopyrine ,Sensitivity and Specificity ,Aged - Abstract
Liver biopsy examination is the gold standard to diagnose the presence of cirrhosis. The aim of this study was to evaluate the accuracy of both 13 C-aminopyrine breath test ( 13 C-ABT) and 13 C-galactose breath test ( 13 C-GBT) in the noninvasive assessment of the presence of cirrhosis in patients with chronic liver disease.We evaluated 61 patients with chronic liver disease of diverse etiologies (21 compensated cirrhosis). All patients underwent 13 C-GBT and 13 C-ABT, and the results were expressed as a percentage of the administered dose of 13 C recovered per hour (%dose/h) and as the cumulative percentage of administered dose of 13 C recovered over time (%dose cumulative). Results were analyzed according to absence vs presence of cirrhosis.On average, 13 C-GBT %dose/h and %dose cumulative were decreased significantly in patients with compensated cirrhosis, and the same finding was observed for 13 C-ABT results from 30 to 120 minutes. 13 C-GBT %dose/h at 120 minutes had 71.4% sensitivity, 85.0% specificity, and 83.7% accuracy, whereas 13 C-ABT %dose cumulative at 30 minutes had 85.7% sensitivity, 67.5% specificity, and 77.1% accuracy for distinguishing between the 2 subgroups of patients. Combined assessment of 13 C-GBT and 13 C-ABT increased the diagnostic accuracy (80% positive predictive value) of either test alone and reached 92.5% specificity and 100% sensitivity for the diagnosis of cirrhosis.In patients with chronic liver disease, both 13 C-GBT and 13 C-ABT are useful for the diagnosis of cirrhosis. Combination of the tests increases the diagnostic yield of each test alone.
- Published
- 2005
17. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?
- Author
-
Federica Botta, Giacomo Borgonovo, Simone Polegato, Roberto Testa, Michele Bellotti, Federica Malfatti, Emanuela Testa, Sara Milazzo, Alessandra Fumagalli, Bruno Chiarbonello, and Edoardo G. Giannini
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,viruses ,Gastroenterology ,Severity of Illness Index ,Impaired renal function ,Liver disease ,chemistry.chemical_compound ,Model for End-Stage Liver Disease ,Internal medicine ,Severity of illness ,Medicine ,Humans ,heterocyclic compounds ,Aged ,Creatinine ,Models, Statistical ,Hepatology ,business.industry ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Prognosis ,Surgery ,enzymes and coenzymes (carbohydrates) ,chemistry ,Italy ,ROC Curve ,Cohort ,Child turcotte pugh score ,Female ,business ,Liver Failure - Abstract
Background: The model for end-stage liver disease (MELD) score is a useful tool to assess prognosis in critically ill cirrhotic patients. However, its short-term prognostic superiority over the traditional Child–Turcotte–Pugh (CTP) score has not been definitely confirmed. The creatinine serum level is an important predictor of survival in patients with liver cirrhosis. Aims: To evaluate and compare the short-term prognostic accuracy of the CTP, the creatinine-modified CTP, and the MELD scores in patients with liver cirrhosis. Methods: CTP, creatinine-modified CTP, and MELD scores were calculated in a cohort of 145 cirrhotic patients. The creatinine-modified CTP was calculated as follows: we assessed the mean creatinine serum level and standard deviation (SD) of the 145 study patients, then assigned a score of 1 to patients with creatinine serum levels ≤ to the mean, a score of 2 to patients with creatinine levels between the mean and the mean+1 SD, and a score of 3 to patients with creatinine levels above the mean+1 SD. The creatinine-modified CTP was then calculated by simply adding each patients' creatinine score to their traditional CTP scores. We calculated and compared the accuracy (c-index) of the three parameters in predicting 3-month survival. Results: The creatinine-modified CTP score showed better prognostic accuracy as compared with the traditional CTP (P=0.049). However, the MELD score proved to be better at defining patients' prognosis in the short-term as compared with both the traditional CTP score (P=0.012) and the creatinine-modified CTP (P=0.047). The excellent short-term prognostic accuracy of the MELD score was confirmed even when patients with abnormal creatinine serum levels were excluded from the analysis (c-index=0.935). Conclusions: Adding creatinine values to the CTP slightly improves the prognostic usefulness of the traditional CTP score alone. The MELD score has a short-term prognostic yield that is better than what is provided by both the CTP and CTP creatinine-modified scores, even in cirrhotic patients who are not critically ill. The positive results obtained by using the MELD score were confirmed even after excluding patients with impaired renal function.
- Published
- 2004
18. Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test
- Author
-
Federica, Malfatti, Edoardo, Giannini, Testa, Emanuela, Simone, Polegato, Elena, Podestà, Alessandra, Fumagalli, Tiziana, Cotelessa, Bruno, Chiarbonello, Michele, Bellotti, Federica, Botta, Sara, Milazzo, and Roberto, Testa
- Subjects
Adult ,Male ,Carbon Isotopes ,Sex Characteristics ,Helicobacter pylori ,Age Factors ,Middle Aged ,2-Pyridinylmethylsulfinylbenzimidazoles ,Helicobacter Infections ,Breath Tests ,Clarithromycin ,Metronidazole ,Humans ,Female ,Lansoprazole ,Aminopyrine ,Omeprazole ,Aged - Abstract
Lansoprazole (LAN) is a proton pump inhibitor drug (PPI) metabolized by the P-450 liver cytochrome (CYP-450) system. LAN is used in association with antimicrobial agents in Helicobacter pylori (HP) eradication therapy. The 13C-Aminopyrine breath test (ABT) is a non-invasive tool exploring liver CYP-450 metabolic activity. Since pharmacological interactions may occur during PPI administration, we attempted to evaluate possible interference with liver CYP-450 activity during HP eradication therapy.Fourteen HP positive patients received LAN (30 mg b.i.d.), clarithromycin (500 mg b.i.d.) and metronidazole (500 mg b.i.d.) for one week. Prior to therapy, and at day 8, each patient underwent 13C-ABT. The 13CO2 concentration in breath samples was measured every 15 minutes from t0 to t120. Results are expressed as cumulative percentage of the administered dose of 13C recovered over time (% 13C dose cum), and as a percentage of the administered dose of 13C recovered per hour (% l3C dose/h). Comparisons were carried out by the Wilcoxon test. Data are presented as mean +/- SD.At day 8, mean ABT was no different from baseline values, both considering % 13C dose cum and% 13C dose/h at each sampling time (e.g.,% 13C dose cum120 which is the most expressive value of the parameters taken into consideration, baseline vs day 8: 10.88 +/- 3.81 vs 10.13 +/- 3.57).These results show that LAN administration and the concomitant use of antimicrobial drugs during HP eradication therapy do not seem to be associated with significant modifications in liver CYP-450 activity.
- Published
- 2004
19. High ascitic fluid leptin levels in patients with decompensated liver cirrhosis and sterile ascites: Relationship with TNF-alpha levels
- Author
-
Tommaso Barreca, Bruno Chiarbonello, Edoardo G. Giannini, Gian Luca Tenconi, Federica Malfatti, Paola Romagnoli, Federica Botta, Mario Mamone, and Roberto Testa
- Subjects
Leptin ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Physiology ,Body Mass Index ,Spontaneous bacterial peritonitis ,Internal medicine ,Ascites ,Electric Impedance ,medicine ,Ascitic Fluid ,Humans ,Prospective Studies ,Aged ,Tumor Necrosis Factor-alpha ,business.industry ,digestive, oral, and skin physiology ,Gastroenterology ,Middle Aged ,Hepatology ,medicine.disease ,Endocrinology ,Adipose Tissue ,Body Composition ,Female ,medicine.symptom ,business ,Body mass index ,hormones, hormone substitutes, and hormone antagonists ,Homeostasis ,Hormone - Abstract
Leptin is an adipocyte-derived hormone involved in the homeostasis of body composition. An imbalance in leptin regulation has been observed in patients with liver cirrhosis. We aimed to assess serum and ascitic leptin levels in a group of patients with decompensated liver cirrhosis and to evaluate the relationship of these levels with tumor necrosis factor alpha (TNF-alpha). We assessed both serum and ascitic fluid leptin levels in a series of 16 consecutive patients with liver cirrhosis. We calculated the body mass index (BMI) and assessed body fat (BF) of all patients by means of bioelectric impedence analysis. Leptin levels were analyzed in relationship to biochemical indexes, TNF-alpha levels, and body composition. None of the patients had spontaneous bacterial peritonitis. Both serum and ascites leptin levels were correlated with BMI and BF. On average, ascitic fluid leptin levels (13.1 +/- 10.9 ng/ml) were twice as high as serum levels (7.0 +/- 6.4 ng/ml), and the ascitic fluid/serum ratio of leptin was1 in all patients. Serum and ascites leptin levels were positively correlated (rS = 0.675, P = 0.009), while no correlation was observed between leptin and TNF-alpha levels, both in serum and in ascites. Serum and ascites TNF-alpha were not correlated. The ascitic fluid leptin levels of cirrhotic patients with sterile ascites are on average two times higher than circulating levels of this hormone. Noteworthily, they correlate significantly with body composition. These findings seem to suggest that in patients with decompensated liver cirrhosis, intraabdominal production of leptin may contribute to the metabolic picture.
- Published
- 2004
20. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection
- Author
-
Alessandra Fumagalli, Edoardo G. Giannini, Roberto Testa, Bruno Chiarbonello, Elena Podestà, Paolo Borro, Federica Malfatti, Emanuela Testa, Simone Polegato, Federica Botta, and Mario Mamone
- Subjects
Adult ,Liver Cirrhosis ,Male ,Hepatitis C virus ,medicine.disease_cause ,Chronic liver disease ,Risk Assessment ,Sensitivity and Specificity ,Severity of Illness Index ,Statistics, Nonparametric ,Cohort Studies ,Liver Function Tests ,hemic and lymphatic diseases ,Medicine ,Humans ,In patient ,Thrombopoietin ,Aged ,Probability ,Hepatology ,business.industry ,Gastroenterology ,hemic and immune systems ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Prognosis ,Virology ,Immunology ,Female ,Liver function ,Viral disease ,business ,Biomarkers ,circulatory and respiratory physiology - Abstract
Thrombopoietin (Tpo) is an important regulator of megakaryocyte maturation and platelet production, and is mainly produced by the liver. A decrease in Tpo production is partly responsible for the thrombocytopenia observed in patients with chronic liver disease (CLD). The aim of this study was to evaluate the relationship between Tpo serum levels and liver function in patients with CLD related to hepatitis C virus (HCV) infection.We studied 37 patients with various degrees of HCV-related CLD. Of the patients, 17 had chronic hepatitis and 20 liver cirrhosis. Liver function was evaluated in all patients by the following hepatic blood flow dependent and independent tests that explore various hepatic metabolic functions: carbon-13 (13C)-aminopyrine breath test (13C-ABT), 13C-galactose breath test (13C-GBT), and monoethylglycinexylidide (MEGX) test. Liver function tests results were correlated with Tpo serum levels.Tpo serum levels were significantly lower in patients with liver cirrhosis (88 +/- 23 pg/ml) as compared to those in patients with chronic hepatitis (128 +/- 55 pg/ml, p=0.0031). However, they did not correlate with serum albumin, bilirubin, or prothrombin activity. Tpo serum levels showed a significant positive correlation with 13C-ABT results (hourly dose at 30 min, rs=0.489, p=0.002; cumulative dose at 120 min, rs=0.425, p=0.008). Moreover, they showed a fair, positive correlation with 13C-GBT hourly dose at 30 min (rs=0.366, p=0.028), and a trend toward a positive correlation with the various MEGX test sampling times (MEGX15, rs=0.314, p=0.059; MEGX30, rs=0.284, p=0.088; and MEGX60, rs=0.320, p=0.059).In this study we have shown that a progressive decline in liver function in patients with HCV-related CLD is paralleled by a decrease in Tpo production. The different correlations observed between Tpo and the various liver function tests suggests that this finding is mainly the result of a decrease in hepatic functional mass rather than dependent on alteration in splanchnic hemodynamic.
- Published
- 2003
21. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis
- Author
-
Roberto Testa, Federica Botta, Emanuela Testa, Domenico Risso, Maria Raffaella Mele, Paola Romagnoli, Paolo Borro, Edoardo G. Giannini, Vincenzo Savarino, Carlo Mansi, and Alberto Fasoli
- Subjects
medicine.medical_specialty ,Cirrhosis ,business.industry ,Gastroenterology ,Retrospective cohort study ,Spleen ,Chronic liver disease ,medicine.disease ,medicine.anatomical_structure ,Liver ,Internal medicine ,Predictive value of tests ,medicine ,Platelet ,Complication ,Varices ,business - Abstract
Background and aims: Cirrhotic patients frequently undergo screening endoscopy for the presence of oesophageal varices (OV). In the future, this social and medical burden will increase due to the greater number of patients with chronic liver disease and their improved survival. In this study, our aims were (1) to identify clinical, biochemical, and ultrasonographic parameters which might non-invasively predict the presence of OV in patients with liver cirrhosis; (2) to evaluate the reproducibility of the obtained results in a different, although related, further group of patients; and (3) to assess the predictiveness of the identified rules in patients with compensated cirrhosis. Methods: In the first part of the study we retrospectively evaluated the presence of OV in 145 cirrhotic patients, and in the second part we evaluated the reproducibility of the study results in a subsequent group of 121 patients. Finally, we evaluated these parameters in a subgroup of 145 patients with compensated disease. All 266 patients underwent a complete biochemical workup, upper digestive endoscopy, and ultrasonographic measurement of spleen bipolar diameter. Platelet count/spleen diameter ratio was calculated for all patients. Results: The prevalence rates of OV were 61% and 58% in the first and second groups of patients, respectively. In the first part of the study, we found that platelet count, spleen diameter, platelet count/spleen diameter ratio, and Child- Pugh class were significantly different among patients with or without OV, although the platelet count/spleen diameter ratio was the only parameter which was independently associated with the presence of OV in a multivariate analysis. A platelet count/spleen diameter ratio cut off value of 909 had 100% negative predictive value for a diagnosis of OV. This result was reproduced in the second group of patients as well as in patients with compensated disease. In a cost-benefit analysis, screening cirrhotic patients according to the “platelet count/spleen diameter ratio strategy” was far more cost effective compared with the “scope all strategy”. Conclusions: The platelet count/spleen diameter ratio is the only parameter which is independently associated with the presence of OV, and its negative predictive value is reproducible. Its use is of value even in the subgroup of patients with compensated disease, and it is also cost effective.
- Published
- 2003
22. Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients
- Author
-
Edoardo, Giannini, Alberto, Fasoli, Federica, Botta, Paola, Romagnoli, Federica, Malfatti, Bruno, Chiarbonello, Mario, Mamone, Vincenzo, Savarino, and Roberto, Testa
- Subjects
Adult ,Liver Cirrhosis ,Male ,Carcinoma, Hepatocellular ,Helicobacter pylori ,Liver Neoplasms ,Hepatitis C, Chronic ,Middle Aged ,Helicobacter Infections ,Cell Transformation, Neoplastic ,Cytochrome P-450 Enzyme System ,Liver ,Liver Function Tests ,Risk Factors ,Gastritis ,Humans ,Female ,Aged ,Retrospective Studies - Abstract
Helicobacter pylori gastric infection has been associated with various digestive and extradigestive diseases. In liver disease bacterial infections have been associated with impairment of cytochrome P-450 liver metabolic activity. Moreover, infection by Helicobacter spp. seems to be linked with the development of hepatocellular carcinoma (HCC) in mice. Our aims were to evaluate the influence of H. pylori infection on cytochrome P-450 liver metabolic activity as assessed by means of monoethylglycinexylidide (MEGX) test and to assess the prevalence of H. pylori infection in patients with HCC. Ninety-six hepatitis C virus (HCV) -positive cirrhotic patients, 36 of whom had HCC, were tested for H. pylori infection by means of anti-H. pylori IgG. Patients underwent the MEGX test. Characteristics of the patients were then analyzed on the basis of the presence of H. pylori infection. Seroprevalence of H. pylori infection was similar between cirrhotic patients without (68%) or with (63.8%) HCC. Mean MEGX values were significantly (P0.0001) lower in H. pylori infected patients (18.2 +/- 13.9 ng/ml) as compared to the noninfected ones (46.9 +/- 17.1 ng/ml), independently of Child-Pugh's classification. These differences persisted even after subdividing patients according to the presence of HCC. In conclusion, in anti-HCV positive cirrhotic patients H. pylori infection is associated to an impairment of cytochrome P-450 liver metabolic activity. Seroprevalence of H. pylori infection in HCC patients is similar to that observed in tumor-free cirrhotics.
- Published
- 2003
23. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease
- Author
-
Emanuela Testa, Paola Romagnoli, Paola Ceppa, Federica Malfatti, Federica Botta, Roberto Testa, Alberto Fasoli, Edoardo G. Giannini, Bruno Chiarbonello, and Domenico Risso
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Cirrhosis ,Hepatitis C virus ,Prothrombin level ,Aspartate transaminase ,medicine.disease_cause ,Chronic liver disease ,digestive system ,Gastroenterology ,fluids and secretions ,Internal medicine ,polycyclic compounds ,Internal Medicine ,medicine ,Health Status Indicators ,Humans ,Aspartate Aminotransferases ,Retrospective Studies ,biology ,business.industry ,virus diseases ,Alanine Transaminase ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Prognosis ,digestive system diseases ,Alanine transaminase ,biology.protein ,Disease Progression ,Female ,Liver function ,business - Abstract
The aspartate aminotransferase-alanine aminotransferase ratio (AST/ALT ratio) has been used to noninvasively assess the severity of disease in patients with chronic liver disease (CLD). We previously demonstrated that progressive liver functional impairment is associated with an increase in the AST/ALT ratio.To evaluate the reproducibility and transportability of the AST/ALT ratio in a large cohort of patients with different degrees of hepatitis C virus (HCV)-related CLD, to confirm the correlation between progressive impairment of liver function and increase in the AST/ALT ratio, to evaluate whether diagnostic accuracy of the ALT/AST ratio can be improved by using it with other biochemical variables, and to assess the 1-year prognostic capability of the AST/ALT ratio in patients with liver cirrhosis.We retrospectively evaluated 252 patients with HCV-related CLD. The AST/ALT ratio was correlated with the degree of liver fibrosis in patients with chronic hepatitis and with the Child-Pugh score in patients with cirrhosis. All patients had undergone monoethylglycinexylidide (MEGX) testing to evaluate liver function. We assessed the prognostic ability of the AST/ALT ratio in a subset of 63 cirrhotic patients who were followed up for at least 1 year.The AST/ALT ratio was more frequently 1 or higher in cirrhotic patients (P.001). There was a significant correlation between MEGX values and the AST/ALT ratio (r(s) = -0.621, P.001). Multivariate stepwise logistic analysis showed that AST/ALT ratio, platelet count (PLT), MEGX values, and prothrombin activity were independently associated with the presence of cirrhosis. Combined assessment of the AST/ALT ratio and/or PLT obtained 97.0% positive predictive value and 97.9% negative predictive value for the diagnosis of cirrhosis. The AST/ALT ratio had 81.3% sensitivity and 55.3% specificity in identifying cirrhotic patients who died within 1-year of follow-up.The AST/ALT ratio is both reproducible and transportable in patients with HCV-related CLD. The AST/ALT ratio is correlated with both histologic stage and clinical evaluation. Progressive liver functional impairment is reflected by an increase in the AST/ALT ratio. Noninvasive evaluation by means of the combined AST/ALT ratio and PLT assessment misclassifies only a few cirrhotic patients. In cirrhotic patients, the AST/ALT ratio provides medium-term prognostic information that is no different from that provided by established prognostic scores.
- Published
- 2003
24. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma
- Author
-
Edoardo G. Giannini, Alberto Fasoli, Domenico Risso, Roberto Testa, Federica Botta, and Paola Romagnoli
- Subjects
Oncology ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Aging ,Cirrhosis ,Carcinoma, Hepatocellular ,Gastroenterology ,Internal medicine ,Severity of illness ,Carcinoma ,Medicine ,Humans ,Risk factor ,Survival rate ,Cancer staging ,Aged ,Retrospective Studies ,business.industry ,Age Factors ,Retrospective cohort study ,General Medicine ,Hepatitis C Antibodies ,medicine.disease ,Prognosis ,Hepatitis C ,Survival Rate ,Hepatocellular carcinoma ,Female ,Geriatrics and Gerontology ,business - Abstract
Background: hepatitis C virus infection-related cirrhosis is a major risk factor for the development of hepatocellular carcinoma. Hepatocellular carcinoma in anti-hepatitis C virus positive cirrhotics shows an increasing prevalence with ageing, although it is not clear whether the age of the patients can be considered a critical factor in the overall assessment of severity of disease or in the choice of therapeutic procedures and prognosis. Objective: to evaluate the influence of older age on modality of presentation, therapeutic choices, outcome, and survival in anti-hepatitis C virus patients with hepatocellular carcinoma. Methods: we retrospectively evaluated 75 anti-hepatitis C virus positive cirrhotic patients with hepatocellular carcinoma consecutively referred to our unit. Patients were sub-divided into two sub-groups according to their age (-65 or 065 years) at tumor diagnosis. The characteristics of the patients and of hepatocellular carcinoma, therapeutic procedures, and survival were then analyzed. Results: median age of the patients was 68 years and mean duration of infection was 24 years. Clinical characteristics of older hepatocellular carcinoma patients were no different from those of younger ones. Hepatocellular carcinoma was more frequently of diffuse type in patients aged -65 years. However, therapeutic options were no different between the two sub-groups of patients, and a similar proportion of patients did not undergo therapy in either group. Overall, 1- and 2-year survival rates were 73% and 51%, respectively. After a mean follow-up of 21 months a higher number of patients aged -65 years died (p=0.002). Moreover, Kaplan-Meier curves showed longer survival in patients aged 065 years (p=0.002). Lastly, diffuse type of hepatocellular carcinoma and tumor staging were the variables independently associated with worse survival in multivariate regression analysis. Conclusions: hepatocellular carcinoma appears in older anti-hepatitis C virus positive cirrhotic patients showing long duration of infection. Older age of the patients does not seem to influence therapeutic options, and more importantly does not exclude patients from treatment. Lastly, older patients seem to have better prognosis most likely due to hepatocellular carcinoma characteristics, since hepatocellular carcinoma seems to present with more unfavourable characteristics in younger cirrhotic patients.
- Published
- 2002
25. Monitoring of liver metabolic function during interferon-alpha therapy and its relationship to treatment outcome in chronic hepatitis C patients
- Author
-
Edoardo, Giannini, Alberto, Fasoli, Paola, Romagnoli, Federica, Botta, Alessandra, Fumagalli, Simone, Polegato, Simona, Sola, Paola, Ceppa, and Roberto, Testa
- Subjects
Adult ,Male ,Treatment Outcome ,Liver Function Tests ,Humans ,Interferon-alpha ,Lidocaine ,Female ,Hepatitis C, Chronic ,Middle Aged ,Antiviral Agents ,Aged - Abstract
Interferon is considered the cornerstone in the therapy of chronic hepatitis C patients. Experimental studies have shown that interferon administration may influence liver metabolic activity. However, data concerning the monitoring of liver metabolic function during a therapeutic course of interferon in chronic hepatitis C patients are scanty. The MEGX (monoethylglycinexylidide) test has been used in diagnostic and prognostic assessment of chronic liver disease as a quantitative liver function test. In this study our aim was to non-invasively monitor liver function in chronic hepatitis C patients during a course of interferon-alpha therapy and to evaluate whether the presence of modifications in liver metabolic function might influence the therapeutic outcome.We studied 22 patients with biopsy-proven chronic hepatitis C before, during (1st, 3rd and 6th month of therapy), and three months after interferon-alpha (3 million units thrice weekly for six months) using MEGX test to monitor liver function.During the longitudinal study no significant differences were observed between pretreatment MEGX30 values and those obtained during interferon treatment or at the end of follow-up, both considering patients together or grouped according to treatment outcome (Responders vs. Non-responders). Analysis of the MEGX30 variations during therapy showed that they were evenly distributed between responder and non-responder patients. Furthermore, during interferon therapy none of the patients reached a MEGX30 value compatible with severely impaired liver function.Our results suggest that although a discrete prevalence of modifications in liver metabolic function occurs in chronic hepatitis C patients during interferon therapy they do not seem to have clinical relevance or influence therapeutic outcome.
- Published
- 2002
26. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis
- Author
-
Edoardo G. Giannini, Paola Romagnoli, Federica Malfatti, Simone Polegato, Emanuela Testa, Federica Botta, Domenico Risso, Bruno Chiarbonello, Roberto Testa, and Alessandra Fumagalli
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Hepatitis B virus ,Cirrhosis ,Time Factors ,Hepacivirus ,digestive system ,Gastroenterology ,Sensitivity and Specificity ,Severity of Illness Index ,Liver disease ,Model for End-Stage Liver Disease ,Liver Function Tests ,Predictive Value of Tests ,Internal medicine ,Medicine ,Humans ,Aspartate Aminotransferases ,Survival analysis ,Retrospective Studies ,Hepatology ,medicine.diagnostic_test ,Receiver operating characteristic ,business.industry ,AST/ALT ratio ,Alanine Transaminase ,medicine.disease ,Prognosis ,Survival Analysis ,digestive system diseases ,Surgery ,body regions ,ROC Curve ,business ,Liver function tests ,Viral hepatitis - Abstract
OBJECTIVES: The AST/ALT ratio has shown good diagnostic accuracy in patients with chronic viral liver disease. However, its prognostic utility has never been tested. Recently, the Model for End-Stage Liver Disease (MELD) has been proposed as a simple and effective tool to predict survival in patients with liver cirrhosis. The aims of this study were to assess the 3-month and 1-yr prognostic ability of the AST/ALT ratio in a series of patients with virus-related liver cirrhosis, and to evaluate the relationship between the AST/ALT ratio and the MELD score and to compare their prognostic ability. METHODS: The AST/ALT ratios and MELD scores of 99 patients with liver cirrhosis of viral etiology (73 patients with hepatitis C virus and 26 with hepatitis B virus) who had been followed-up for at least 1 yr were retrospectively calculated and correlated with the patients’ 3-month and 1-yr prognosis. Receiver operating characteristic curves were used to determine the AST/ALT ratio and the MELD score cut-offs with the best sensitivity (SS) and specificity (SP) in discriminating between patients who survived and those who died. Univariate survival curves were estimated by the Kaplan-Meier method using the cut-offs identified by means of receiver operating characteristic curves. RESULTS: AST/ALT ratios and MELD scores showed a significant correlation (rs = 0.503, p = 0.0001). In all, 8% and 30% of the patients had died after 3 months and 1 yr of follow-up, respectively. AST/ALT ratios and MELD scores were significantly higher among the patients who died during both 3-month and 1-yr follow-up. An AST/ALT ratio cut-off of 1.17 had 87% SS and 52% SP, whereas a MELD cut-off of 9 had 57% SS and 74% SP in discriminating between patients who survived and those who died after 1 yr. The combined assessment of the AST/ALT ratio and/or MELD score had 90% SS and 78% SP. Survival curves of the patients showed that both parameters clearly discriminated between patients who survived and those who died in the short term (AST/ALT ratio, p = 0.0094; MELD score, p = 0.0089) as well as in the long term (AST/ALT ratio, p < 0.0005; MELD score, p = 0.004). CONCLUSIONS: In patients with virus-related cirrhosis, the AST/ALT ratio has prognostic capability that is not significantly different from that of an established prognostic score such as MELD. Combined assessment of the two parameters increases the medium-term prognostic accuracy.
- Published
- 2002
27. Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?
- Author
-
Umberto Valente, Domenico Risso, P. B. Lantieri, Roberto Testa, Alberto Fasoli, Edoardo G. Giannini, Guido Celle, S. Caglieris, Federica Botta, and Dardano G
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Prognostic variable ,Cirrhosis ,medicine.medical_treatment ,Humans ,Liver Transplantation ,MEGX Test ,Liver transplantation ,Gastroenterology ,Bile Acids and Salts ,Liver disease ,Predictive Value of Tests ,Internal medicine ,Ascites ,medicine ,Prospective Studies ,Prospective cohort study ,Aged ,Hepatology ,business.industry ,Lidocaine ,Middle Aged ,medicine.disease ,Prognosis ,Transplantation ,ROC Curve ,Predictive value of tests ,Female ,medicine.symptom ,business - Abstract
Liver transplantation is nowadays the therapeutic option for end-stage liver disease. Correct disease staging is the main step towards improving the timing of listing for liver transplantation so as to avoid premature or late entry. The need for correct prognostic evaluation is due to the limited number of donors and to the increasing number of patients awaiting transplantation. Our aim was to verify whether Child-Pugh's score might be improved by adding the monoethylglycinexylidide (MEGX) formation test and/or serum bile acid determination.We evaluated 182 cirrhotic patients (44 Child-Pugh class A, 97 class B, and 41 class C) of mixed aetiology referring to a tertiary care centre for functional staging of liver disease. These patients were prospectively followed-up for 12-72 months. During this period, 45 patients died, 46 received a transplant, and 91 survived without transplantation. The end-point of analysis was either survival or liver disease-related death at the 6th, 12th, 18th and 24th months of follow-up. The 46 transplanted patients were excluded from the study upon transplantation.In our study, a cut-off for Child-Pugh's score8 confirmed its usefulness, especially in short-term prognostic prediction, while mid- and long-term prediction improved by almost 10% by using the combination of a Child- Pugh's score8 and an MEGX value15 mg/l. Cox's multi-variate regression analysis indicated that MEGX values either with Child-Pugh's score or with prothrombin activity and ascites were independent prognostic variables.Besides confirming that Child-Pugh's score as the basis of prognostic evaluation of cirrhotic patients, these results suggest that the MEGX test might be a complement to the original score when a patient is being evaluated for a liver transplantation programme.
- Published
- 2001
28. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels
- Author
-
Alberto Fasoli, Gian Carlo Icardi, Luca Mastracci, Francesca Faravelli, Paola Ceppa, Edoardo G. Giannini, Federica Botta, Domenico Risso, Roberto Testa, P. B. Lantieri, and Paola Romagnoli
- Subjects
Adult ,Male ,hepatitis C virus ,medicine.medical_specialty ,Cirrhosis ,Genotype ,Hepatitis C virus ,medicine.disease_cause ,Gastroenterology ,histology ,iron ,Fibrosis ,Internal medicine ,Immunopathology ,chronic hepatitis ,fibrosis ,alpha-glutathione S-transferase ,hepatitis C virus RNA ,medicine ,Humans ,Glutathione Transferase ,Hepatology ,biology ,business.industry ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Ferritin ,Liver ,Immunology ,biology.protein ,Female ,Histopathology ,business ,Viral load - Abstract
BACKGROUND Host and viral factors have been suggested as possible causative factors for the presence of liver iron accumulation in chronic hepatitis C. However, there is no agreement regarding the influence of liver iron accumulation on the biochemical and histological severity of chronic hepatitis C. Moreover, data concerning the relationships between both viral load and genotype and liver iron accumulation are scanty. AIMS To evaluate the biochemical, histological and virological assessment of a group of chronic hepatitis C patients without risk factors for iron overload, on the basis of the presence, degree and distribution of liver iron accumulation. METHODS Fifty-three chronic hepatitis C patients (34 men, 19 women; age 44 +/- 11 years) with no risk factors for liver iron accumulation and showing no HFE mutations were chosen from a broader cohort of chronic hepatitis C patients. The presence, degree and distribution of liver iron accumulation were assessed using Deugnier's score. Relationships between the presence of liver iron accumulation and grading and staging were carried out separately. Hepatitis C virus RNA serum levels and viral genotype were compared in patients with or without liver iron accumulation. Alpha glutathione S-transferase serum levels were assessed in all patients. RESULTS Overall, liver iron accumulation was mild and was present in 19 patients (36%). It was associated with male gender (P = 0.0358), and was reflected by high serum iron levels (P = 0.001) and high ferritin levels (P < 0.0001). Hepatitis C virus RNA levels and genotype were not associated with the presence of liver iron accumulation. In multivariate analysis, ferritin was the only variable significantly associated with liver iron accumulation (P < 0.0001). Grading was higher in patients with liver iron accumulation regardless of the site of iron deposition. Fibrosis was present in all patients with iron overload; these patients were more frequently cirrhotic. Moreover, patients with mesenchymal or mixed deposition had higher staging than patients with hepatocytic or no iron deposition. This feature was reflected by higher alpha-glutathione S-transferase levels. CONCLUSIONS Liver iron accumulation is mild in chronic hepatitis C patients without HFE mutations and is mainly reflected by serum ferritin levels. Viral characteristics do not seem to play a role in iron deposition. Liver iron accumulation is associated with higher grading, advanced fibrosis and cirrhosis. Moreover, higher staging is associated with mesenchymal or mixed iron deposition. In these patients, higher alpha-glutathione S-transferase levels seem to reflect more complex damage.
- Published
- 2001
29. The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis
- Author
-
Federica Botta, Roberto Testa, Edoardo G. Giannini, Alberto Fasoli, Paola Romagnoli, and Domenico Risso
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Lidocaine ,Chronic liver disease ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Adverse effect ,Aged ,Hepatitis, Chronic ,Pharmacology ,Hepatitis ,business.industry ,Hepatology ,Middle Aged ,medicine.disease ,Surgery ,Blood pressure ,Anesthesia ,Hepatic Encephalopathy ,Female ,Liver function ,business ,medicine.drug - Abstract
Lidocaine (LID) is an aminoethylamide used in hepatology to perform the monoethylglycinexylidide (MEGX) test for the evaluation of liver function in patients with cirrhosis (CIR) or chronic hepatitis (CH). The authors evaluated whether the MEGX test changes psychometric performance in patients with chronic liver disease and, in particular, whether it might trigger subclinical portosystemic encephalopathy in patients with CIR. Thirty patients with CIR and 20 patients with CH were studied. They underwent a standard-dose MEGX test, before and after which a psychometric test was administered and blood pressure, heart rate, and adverse effects were recorded. The MEGX test did not modify psychometric performance. Mean arterial blood pressure and heart rate did not change at the end of the MEGX test in either patients with CH or CIR. Adverse effects were present in 66% of all patients during lidocaine injection and lasted up to 3 minutes afterwards. They were more frequent in patients with CH than in patients with CIR (85% vs 53%). No relationship was found between adverse effects and lidocaine dosage, nor between adverse effects and MEGX or lidocaine concentration at 15 minutes. Standard-dose MEGX test does not worsen or trigger portosystemic encephalopathy in CIR. Adverse effects were frequent but mild.
- Published
- 2000
30. Histologic determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C
- Author
-
Roberto Testa, Alberto Fasoli, Domenico Risso, Edoardo G. Giannini, Paola Ceppa, Paola Romagnoli, and Federica Botta
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Necrosis ,Chronic liver disease ,Fibrosis ,medicine ,Humans ,Pharmacology (medical) ,Grading (tumors) ,Aged ,Pharmacology ,medicine.diagnostic_test ,Bile duct ,business.industry ,Lidocaine ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Regression Analysis ,Female ,Liver function ,medicine.symptom ,Steatosis ,business ,Liver function tests - Abstract
Patients affected by chronic hepatitis C (CHC) display a peculiar histologic picture characterized by the presence of steatosis and bile duct damage in addition to evidence of inflammation, necrosis, and fibrosis. In the staging of these patients, functional evaluation may be considered a complementary tool. The monoethylglycinexylidide (MEGX) test has been used in diagnostic and prognostic assessment of chronic liver disease as a quantitative liver function test. In this study the authors evaluated whether different sampling times for the test could reflect different histologic patterns. The authors studied 82 patients with biopsy-proven CHC who underwent functional evaluation by means of MEGX test. The authors found that MEGX15 better reflected the histologic findings of necrosis and inflammation, and MEGX60 the presence of fibrosis. Neither steatosis nor bile duct damage showed a strong correlation with either sampling time. Moreover, MEGX levels showed a progressive decrease as histologic grading of chronic hepatitis progressively increased. Stepwise regression analysis identified necrosis and inflammation as histologic variables associated with both MEGX15 and MEGX30, and fibrosis as a variable associated with MEGX60. These results suggest that a decline in liver metabolic function corresponds to a progressive increase in liver damage, and that this circumstance should be taken into account when prescribing drugs to patients with CHC.
- Published
- 2000
31. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis
- Author
-
A. Cataldi, Pasquale Tenerelli, Ermanno Rolandi, Tommaso Barreca, Roberto Testa, Edoardo G. Giannini, Federica Botta, Alberto Fasoli, and Roberto Franceschini
- Subjects
Adult ,Leptin ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Liver disease ,Hepatitis B, Chronic ,Reference Values ,Internal medicine ,medicine ,Humans ,Hepatology ,business.industry ,Lidocaine ,Hepatitis C ,Organ Size ,Hepatitis B ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Endocrinology ,Adipose Tissue ,Female ,Liver function ,Viral hepatitis ,business ,Body mass index - Abstract
Serum levels of leptin, the adipocyte-derived hormone regulating food intake and energy expenditure in mammals, have been found to be increased in cirrhotic patients. The aim of the present study was to investigate leptin serum level in relation to anthropometric features and liver function in patients with viral chronic hepatitis or liver cirrhosis.Serum leptin levels were determined by radioimmunoassay in 30 male and 10 female patients with chronic hepatitis, in 42 male and 10 female patients with liver cirrhosis, and in four respective control groups. Liver function was evaluated by the monoethylglycinexylidide formation test. Body mass index and body fat mass were estimated by weight, height and skinfold thickness measurements.Compared with controls, absolute serum leptin levels were significantly (p0.01) lower in chronic hepatitis patients and similar in cirrhotic patients. Leptin serum levels were significantly (p0.05) higher in cirrhotic than in chronic hepatitis patients. When expressed in relation to body fat mass, the above differences persisted; however, cirrhotic females showed significantly (p0.05) higher serum leptin values than controls. Serum leptin values correlated negatively (p0.01) with monoethylglycinexylidide serum values in all groups of patients.In patients with chronic viral liver disease, serum leptin levels tend to increase as liver function worsens. This may reflect a decline in the ability to downregulate energy expenditure as an adaptation to anorexia and/or to defective substrate utilisation due to liver disease and may negatively influence body weight homeostasis in these patients.
- Published
- 2000
32. Is there a role for multiple quantitative liver function tests?
- Author
-
Federica Botta, Paola Romagnoli, Federica Malfatti, Bruno Chiarbonello, Roberto Testa, Edoardo G. Giannini, and Alberto Fasoli
- Subjects
Pathology ,medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,medicine ,Liver function tests ,business - Published
- 2000
33. Bile duct lesions in chronic hepatitis C: biochemical and virological relationship with histological damage
- Author
-
Alberto Fasoli, Domenico Risso, Roberto Testa, A. Pasini, L. Mastacci, Paola Ceppa, Edoardo G. Giannini, Paola Romagnoli, Federica Botta, and L. Comino
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,Hepatology ,Chronic hepatitis ,business.industry ,Bile duct ,Internal medicine ,Medicine ,business ,Gastroenterology - Published
- 2000
34. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens
- Author
-
P. B. Lantieri, Alberto Fasoli, Federica Botta, Federica Malfatti, Roberto Testa, Paola Romagnoli, Domenico Risso, Bruno Chiarbonello, Vincenzo Savarino, and Edoardo G. Giannini
- Subjects
Adult ,Male ,Peptic Ulcer ,Population ,Lansoprazole ,Pharmacology ,2-Pyridinylmethylsulfinylbenzimidazoles ,Helicobacter Infections ,Clarithromycin ,Metronidazole ,medicine ,Cytochrome P-450 Enzyme Inhibitors ,Humans ,Carbon Radioisotopes ,education ,Aminopyrine ,Pantoprazole ,Omeprazole ,Aged ,Breath test ,education.field_of_study ,Hepatology ,medicine.diagnostic_test ,biology ,Helicobacter pylori ,business.industry ,Gastroenterology ,Proton Pump Inhibitors ,Middle Aged ,biology.organism_classification ,Anti-Ulcer Agents ,Breath Tests ,Gastritis ,Sulfoxides ,Benzimidazoles ,Drug Therapy, Combination ,Female ,Liver function ,business ,medicine.drug - Abstract
OBJECTIVE: Proton pump inhibitors and antimicrobial agents are widely used to eradicate Helicobacter pylori (H. pylori) infection. In the general population the prevalence of infection and of polypharmacy increases the possibility of drug–drug interactions during H. pylori eradication therapy. The purpose of the present study was to assess the prevalence, degree, and clinical relevance of metabolic interference with the cytochrome P450 enzymatic system occurring during 1 wk of administration of omeprazole, lansoprazole, or pantoprazole followed by the association of clarithromycin and metronidazole for another week. The 13C aminopyrine breath test (ABT) was chosen to screen for possible interactions. METHODS: We studied 30 patients referred to our Unit for H. pylori eradication therapy. They were randomized to receive either omeprazole (20 mg b.i.d.), lansoprazole (30 mg b.i.d.), or pantoprazole (40 mg b.i.d.) for 2 wk. During the second week clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) were added. ABT was performed before, and at the end of the first and second week of therapy. Percentage of the administered dose of 13C recovered per hour at the peak (percent 13C dose/h at the peak) and cumulative percentage of administered dose of 13C recovered over time at 120 min (percent 13C dose cum120) were the ABT evaluated parameters. RESULTS: At baseline all patients showed a normal liver function. In individual patients during treatment we observed various liver metabolic interactions both as inhibition and induction, as well as after the first and the second week of therapy. However, mean modifications of the ABT parameters during the 2 weeks of therapy were not statistically significant compared to baseline values. None of the patients who had ABT variations complained of side effects. CONCLUSIONS: H. pylori eradication therapy interferes with cytochrome P450-dependent liver metabolic activity. However, the clinical relevance of these metabolic interactions is not yet apparent, and further investigation is needed. H. pylori eradication therapy appears safe, but these interactions should be considered in the choice of proton pump inhibitor and antimicrobial agents.
- Published
- 2000
35. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients
- Author
-
Valentina Venturino, Paola Romagnoli, Elena Cresta, Alberto Fasoli, Guido Celle, Roberto Testa, Edoardo G. Giannini, Federica Botta, Paola Ceppa, and Domenico Risso
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Genotype ,Bile Duct Diseases ,Hepacivirus ,Gastroenterology ,Cholestasis ,Internal medicine ,medicine ,Humans ,Aspartate Aminotransferases ,Sex Distribution ,Hepatology ,medicine.diagnostic_test ,Bile duct ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Fatty liver ,Bilirubin ,Hepatitis C ,gamma-Glutamyltransferase ,Hepatitis C Antibodies ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Alkaline Phosphatase ,Fatty Liver ,medicine.anatomical_structure ,Italy ,Biliary tract ,Liver biopsy ,RNA, Viral ,Female ,Bile Ducts ,Steatosis ,business - Abstract
Background/Aims: Hepatitis C virus (HCV) related disease follows a long, benign course and most affected patients have mild disease. Liver biopsy is mandatory to grade and stage the disease. Characteristic, though non-specific, HCV histological lesions such as bile duct damage and steatosis have been singled out but their association with non-histological parameters has not been completely defined. Our aim was to study the relationships among these histological lesions and clinical, biochemical, functional and virological characteristics in a group of Northern Italian patients with chronic hepatitis. Methods: We studied 172 patients with HCV-related chronic hepatitis. Patients were divided into groups on the basis of histology including bile duct damage and steatosis. Clinical, biochemical, functional and virological profiles were related to histological findings. Results: Histological grading and staging of disease increased as the age of patients increased. Steatosis was present in 70% of our patients and was related to a higher degree of fibrosis and to decreased functional activity. The prevalence of bile duct damage was 20%. This lesion was present in older patients with higher staging and impaired liver function. Biochemically it was associated with an increase in aspartate aminotransferase, gammaglutamyltranspeptidase, alkaline phosphatase, and total bilirubin. Conclusions: In the population we studied, HCV chronic hepatitis was predominantly a mild disease. Moreover both steatosis and bile duct damage were also mild. Steatosis was associated with fibrosis and this might influence liver metabolic function. Bile duct lesions were found in older patients with advanced disease showing biochemical evidence of cholestasis. The molecular role HCV might play in the pathogenesis of these histological features should be addressed in further studies.
- Published
- 1999
36. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer
- Author
-
John R. Lake, Edoardo G. Giannini, Douglas M. Heuman, Anastasios A. Mihas, Patrick S. Kamath, W. Ray Kim, Walter Kremer, Richard B. Freeman, Federica Botta, Roberto Testa, and Russell H. Wiesner
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,In patient ,medicine.disease ,business - Published
- 2003
37. AST/ALT ratio has prognostic value in the assessment of 1-year survival of patients with viral cirrhosis: comparison with MELD and Child-Pugh's scores
- Author
-
Alessandra Fumagalli, Roberto Testa, Bruno Chiarbonello, Simone Polegato, Emanuela Testa, Paola Romagnoli, Edoardo G. Giannini, Federica Botta, and Federica Malfatti
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,AST/ALT ratio ,Internal medicine ,Medicine ,business ,medicine.disease ,Value (mathematics) ,Gastroenterology - Published
- 2002
38. [Untitled]
- Author
-
Roberto Testa, Edoardo G. Giannini, Paola Romagnoli, and Federica Botta
- Subjects
medicine.medical_specialty ,Transplant surgery ,Physiology ,business.industry ,Internal medicine ,Anesthesia ,Gastroenterology ,medicine ,Hepatology ,Intravenous lidocaine ,business ,Administration (government) ,Test (assessment) - Published
- 2000
39. 1236 Prognostic evaluation of hepatocellular carcinoma: a comparative analysis of four different staging systems in anti-HCV patients with liver cirrhosis
- Author
-
Bruno Chiarbonello, Simone Polegato, Elena Podestà, Federica Botta, Federica Malfatti, Alessandra Fumagalli, Eduardo Giannini, Emanuela Testa, Paola Romagnoli, and Roberto Testa
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,Anti hiv ,Internal medicine ,Hepatocellular carcinoma ,medicine ,business ,medicine.disease ,Gastroenterology - Published
- 2003
40. 20 P Correlations between model for end-stage liver disease and 13C aminopyrine breath test in patients with liver cirrhosis
- Author
-
Paola Romagnoli, Alberto Fasoli, Simone Polegato, Roberto Testa, Edoardo G. Giannini, Federica Botta, Bruno Chiarbonello, Federica Malfatti, Emanuela Testa, and Alessandra Fumagalli
- Subjects
Breath test ,medicine.medical_specialty ,Cirrhosis ,Hepatology ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,medicine.disease ,Model for End-Stage Liver Disease ,Internal medicine ,medicine ,In patient ,business - Published
- 2002
41. Relationships between MELD scoring system, Child-Pugh's score, and residual liver function in a European series of cirrhotic patients
- Author
-
Federica Malfatti, Edoardo G. Giannini, Paola Romagnoli, Simone Polegato, Bruno Chiarbonello, Alberto Fasoli, Roberto Testa, Alessandra Fumagalli, Giuliano Colla, Domenico Risso, Federica Botta, and Emanuela Testa
- Subjects
medicine.medical_specialty ,Series (stratigraphy) ,Scoring system ,Hepatology ,business.industry ,Internal medicine ,medicine ,Liver function ,business ,Residual ,Gastroenterology - Published
- 2002
42. Influence of one-week triple (Rabeprazole, clarythromycin, metronidazole) helicobacter pylori eradication therapy on 13C aminopyrine breath test
- Author
-
Emanuela Testa, Federica Malfatti, Vincenzo Savarino, Roberto Testa, C. Gambaro, Simone Polegato, Paola Romagnoli, Alessendra Fumagalli, Bruno Chiarbonello, Elena Podestà, Alberto Fasoli, Edoardo G. Giannini, and Federica Botta
- Subjects
Breath test ,medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,biology ,business.industry ,Gastroenterology ,Rabeprazole ,Helicobacter pylori ,biology.organism_classification ,Metronidazole ,Internal medicine ,medicine ,business ,medicine.drug - Published
- 2001
43. Impairment of cytochrome P-450 dependent liver metabolic activity in cirrhotic patients with Helicobacter pylori (H pylori) infection
- Author
-
Edoardo G. Giannini, Bruno Chiarbonello, Emanuela Testa, Elena Podestà, Paola Romagnoli, Federica Malfatti, Roberto Testa, Federica Botta, Alberto Fasoli, and Simone Polegato
- Subjects
medicine.medical_specialty ,Hepatology ,Cytochrome ,biology ,business.industry ,Gastroenterology ,Helicobacter pylori ,H pylori infection ,biology.organism_classification ,Internal medicine ,biology.protein ,Medicine ,business ,Metabolic activity - Published
- 2001
44. Clinical utility of the AST/ALT ratio alone or in combination with platelet count in the assessment of severity of chronic liver disease related to hepatitis C virus infection (HCV)
- Author
-
Alberto Fasoli, Edoardo G. Giannini, Simone Polegato, Alessandra Funuagalli, Federica Malfatti, Domenico Risso, Bruno Chiarbonello, Elena Podestà, Roberto Testa, Emanuela Testa, Federica Botta, and Paola Romagnoli
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,AST/ALT ratio ,Hepatitis C virus ,Gastroenterology ,Chronic liver disease ,medicine.disease ,medicine.disease_cause ,Virology ,Internal medicine ,medicine ,Platelet ,business - Published
- 2001
45. Influence of one-week triple (Rabeprazole, clarythromycin, metronidazole) Helicobacter pylori eradication therapy on 13C aminopyrine breath test
- Author
-
Federica Malfatti, Bruno Chiarbonello, Simone Polegato, Camilla Gambaro, Federica Botta, Alberto Fasoli, Paola Romagnoli, Emanuela Testa, Alessandra Fumagalli, Edoardo Giannini, Vincenzo Savarino, and Roberto Testa
- Subjects
Hepatology ,Gastroenterology - Published
- 2001
46. Platelets count, Platelets/Spleen dimension ratios and liver function in different degrees of liver disease
- Author
-
Elena Podestd, Bruno Chiarbonello, Alessandra Fumagalli, Roberto Testa, Paola Romagnoli, Federica Malfatti, Edoardo G. Giannini, Federica Botta, Emanuela Testa, Simone Polegato, and Alberto Fasoli
- Subjects
Pathology ,medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Spleen ,medicine.disease ,Liver disease ,medicine.anatomical_structure ,Dimension (vector space) ,Medicine ,Platelet ,Liver function ,business - Published
- 2001
47. Serum (LPTS) and ascitic leptin (LPTA) levels in decompensated cirrhotic patients
- Author
-
Paola Romagnoli, Tommaso Barreca, Edoardo G. Giannini, G. Tenconi, Roberto Testa, Alberto Fasoli, and Federica Botta
- Subjects
medicine.medical_specialty ,Endocrinology ,Hepatology ,business.industry ,Internal medicine ,Leptin ,medicine ,business - Published
- 2001
48. Platelets/spleen area ratio reflects progressive liver disease
- Author
-
Federica Botta, Federica Malfatti, Paola Romagnoli, Bruno Chiarbonello, Roberto Testa, Alberto Fasoli, and Edoardo G. Giannini
- Subjects
Pathology ,medicine.medical_specialty ,medicine.anatomical_structure ,Hepatology ,business.industry ,Immunology ,medicine ,Area ratio ,Platelet ,Spleen ,Progressive liver disease ,business - Published
- 2001
49. Quantitative liver function tests in chronic liver disease
- Author
-
Emanuela Testa, Federica Malfatti, Edoardo G. Giannini, Bruno Chiarbonello, Alberto Fasoli, Paola Romagnoli, Federica Botta, and Roberto Testa
- Subjects
medicine.medical_specialty ,Hepatology ,medicine.diagnostic_test ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Chronic liver disease ,medicine.disease ,business ,Liver function tests - Published
- 2000
50. Monoethylglycinexylidide (MEGX) test can increase prognostic power of clinical score in patients child-pugh score class B during one-year follow-up
- Author
-
Paola Romagnoli, Alberto Fasoli, Roberto Testa, Federica Botta, Emanuela Testa, Edoardo G. Giannini, Bruno Chiarbonello, and Federica Malfatti
- Subjects
Pediatrics ,medicine.medical_specialty ,Hepatology ,One year follow up ,business.industry ,Gastroenterology ,medicine ,In patient ,business ,Child-Pugh score class B ,Test (assessment) - Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.